AstraZeneca and Daiichi Sankyo’s ENHERTU plus pertuzumab showed a median progression-free survival greater than three years First trial in more than a decade to demonstrate an improvement in outcomes in the 1st-line setting for a broad population of patients with HER2-positive metastatic breast cancer WILMINGTON, Del. / Jun 02, 2025 / Business Wire / Positive results from the DESTINY-Breast09 Phase III trial showed ENHERTU ®... Read More